For canine bacterial conjunctivitis caused by susceptible Staphylococcus pseudintermedius and Streptococcus canis, a preserved 10.0% w/v sodium sulfacetamide solution is manufactured as a sterile multi-dose ophthalmic product. The formulation addition ratio is 100.0 mg/mL sodium sulfacetamide on the anhydrous basis, with 0.005% w/v benzalkonium chloride as the antimicrobial preservative, 0.05% w/v edetate disodium as a chelator, 0.2% w/v sodium thiosulfate as an antioxidant, and monobasic/dibasic sodium phosphate buffer adjusted to pH 7.2–7.8. Sterile water for injection is used to volume. The downstream manufacturing process begins with low-shear dissolution in a 316L stainless steel jacketed vessel at 20–25°C, with agitator speed held between 300–500 rpm to avoid vortex-driven oxygen entrainment. After dissolution for 30–45 min, the bulk solution is filtered through a 0.22 µm PVDF membrane at a differential pressure not exceeding 2.0 bar. The filtered solution is fed by peristaltic pumps to a filling line running at 120 units/min, with in-process fill-weight checks taken every 15 min; fill-volume drift beyond ±0.2 mL triggers pump tube replacement due to elastomer fatigue. The terminal product type is a 15 mL LDPE multi-dose ophthalmic dropper bottle with a polypropylene closure. Compliance for this scenario is anchored to USP <71> sterility testing, USP <51> preservative effectiveness testing, USP <791> pH, USP <785> osmolality, and USP <789> particulate matter in ophthalmic solutions. A compliance matrix for this product type is set out below.

The preserved multi-dose container is suitable only for non-food companion animals; use in food-producing species is excluded because sulfonamide residues require withdrawal-period data not established for this drug. Benzalkonium chloride adsorption to LDPE can deplete preservative content over storage; bottle resin should be qualified by extraction studies under 40°C/75% RH for 6 months. Sulfacetamide sodium solutions are prone to oxidative discoloration when trace iron or copper ions enter from piping or closure components; therefore, copper alloys must be removed from the filling zone, and 316L stainless steel contact surfaces should be passivated and verified before batching.

What Limits the Use of Preserved Multi-Dose Containers in Feline Bacterial Keratitis?

Feline bacterial keratitis secondary to herpesvirus-1 epithelial ulceration commonly requires a preservative-free ophthalmic sulfonamide because benzalkonium chloride can further impair corneal epithelial migration. In this application, the formulation addition ratio is 10.0% w/v sodium sulfacetamide, adjusted to 280–300 mOsm/kg with sodium chloride or mannitol, buffered to pH 7.4, and filled without a preservative. The downstream production process operates through aseptic blow-fill-seal technology: pharmaceutical-grade low-density polyethylene is extruded at zone temperatures of 170°C, 180°C, and 190°C, the parison is inflated in a sterile mold under ISO 5 airflow, and the solution is filled at 0.35 mL ± 0.03 mL per unit. The terminal product type is a preservative-free 0.35 mL single-dose LDPE ophthalmic unit, packed five units per aluminum foil laminate pouch. Compliance is governed by EU GMP Annex 1 for sterile manufacturing, ISO 13408-1:2008 for aseptic processing of health care products, FDA 21 CFR Part 211 for finished pharmaceutical current good manufacturing practice, and USP <71> for sterility release.

On production-scale blow-fill-seal lines, mold-vacuum variation and polymer lot-to-lot melt flow index shifts of ±0.15 mm in container wall thickness can alter drop volume at the point of administration; in-process vision inspection at 200 units/min with weight-divider rejection is therefore required. Because no antimicrobial preservative is present, a breach of primary packaging is unrecoverable; leak detection by high-voltage pinhole testing must reject units with defects below the sealing line. The formulation is not suitable for terminal steam sterilization because prolonged heat exposure can darken sulfacetamide sodium in aqueous media. The single-dose format must be labeled for immediate use after opening, and the absence of preservative limits the beyond-use period to the start of administration.

If Equine Corneal Ulceration Requires an Ointment Vehicle, the 10.0% w/w Dispersion Is Processed Differently

Equine corneal ulceration associated with Streptococcus equi subsp. zooepidemicus or Pseudomonas aeruginosa in stable environments requires a sterile ophthalmic ointment because the petrolatum base increases corneal contact time and reduces tear-film dilution. The formulation addition ratio is 10.0% w/w sodium sulfacetamide micronized to a D90 ≤20 µm, 5.0% w/w mineral oil, 2.0% w/w microcrystalline wax, and white petrolatum to 100.0% w/w. The downstream production process starts by melting the petrolatum and wax phase at 70–75°C, cooling to 45–50°C, and then incorporating the sterile API through a 250 µm screen to break soft agglomerates. The dispersion is passed through a triple-roller ointment mill with a gap setting of 30–40 µm; because mill gap drift from heated rollers has been observed to shift the particle-size distribution after 90 min, a mid-batch D90 recheck is required. The terminal product type is a 3.5 g sterile ophthalmic ointment tube with an ophthalmic cannula tip. Sterility release relies on aseptic processing rather than terminal autoclaving, with compliance under USP <71>, USP <51>, USP <755> for ophthalmic ointment weight variation, and 21 CFR 211.113 for aseptic process validation. Ointment-based sulfacetamide is contraindicated when corneal perforation is suspected because petrolatum vehicle migration into the anterior chamber can cause sterile uveitis. This product is restricted to non-food horses; horses intended for slaughter must be excluded from treatment under applicable residue-monitoring rules.

Sulfur Co-Formulation Parameters for Canine Pyoderma Lotion

When sodium sulfacetamide 10.0% w/w is co-formulated with precipitated sulfur 5.0% w/w for canine pyoderma, the suspension stability is governed less by active solubility than by particle-size distribution and pH. The formulation addition ratio includes 0.25% w/w methylcellulose 4000 as a suspending agent, 2.0% w/w polysorbate 80 as a wetting agent, and purified water to 100.0% w/w, adjusted to pH 4.5–5.0 with citric acid. Sulfur must be pre-dispersed in glycerin at 5.0% w/w before introduction into the aqueous phase to prevent floating and creaming. The downstream production process for this non-sterile topical lotion uses a high-shear mixer operating at 2500–3000 rpm for 15–20 min after hydration of the methylcellulose at 10–15°C. Milling through a 100 µm screen reduces sulfur agglomerates; a sulfur D90 ≤10 µm specification is necessary to avoid airless-pump nozzle clogging during patient use. The terminal product type is a 120 mL airless pump bottle containing a compounded topical lotion for canine dermatology.

Because sulfacetamide-sulfur lotions for canine pyoderma are compounded rather than licensed in major regulatory jurisdictions, the governing standard is USP <795> for non-sterile pharmaceutical compounding, with in-process pH and viscosity limits established by the compounding site. The preparation must be labelled for non-food companion animals only and for use under veterinary oversight. Published data for this specific configuration is limited relative to human dermatology products, so batch release should include a minimum 14-day physical stability check for phase separation, sulfur caking, and pH drift. Sulfur particle-size growth beyond 15 µm during storage indicates premature suspension failure and must trigger quarantine of the batch.

In zoological companion medicine, the absence of licensed ophthalmic formulations for rabbits, ferrets, and small psittacines shifts manufacturing responsibility to extemporaneous sterile compounding from veterinary-grade sodium sulfacetamide API. The formulation addition ratio is 10.0% w/v sodium sulfacetamide in sterile water for injection, adjusted to 280–300 mOsm/kg with 0.9% w/v sodium chloride, and filtered through a 0.22 µm PVDF membrane inside an ISO 5 laminar-flow hood. The compounding process follows USP <797> medium-risk aseptic preparation requirements: a single batch is prepared from API with a certificate of analysis showing bacterial endotoxin below 0.5 EU/mg, aseptic filtration is performed with a disposable syringe filter, and the final solution is dispensed into a 5 mL amber glass ophthalmic dropper. The terminal product type is a preservative-free sterile ophthalmic solution for single-patient use in non-food zoological species. The assigned beyond-use date is 14 days refrigerated at 4–8°C, and the label must state that the product is not for food-producing animals. In psittacine patients, corneal sensitivity to sulfonamide vehicles can differ from mammalian ocular tissue; therefore, initial application should be limited to one drop per eye under direct veterinary observation. There is no terminal sterilization step, so the aseptic technique, environmental monitoring, and gloved fingertip sampling records are release-critical controls under USP <797>.

Oral Capsule Compounding, Susceptibility Confirmation, and the Limits of Unlicensed Systemic Use

In non-food companion animals with lower urinary tract infection caused by sulfonamide-susceptible Escherichia coli confirmed by broth microdilution, sodium sulfacetamide may be compounded into oral capsules as an alternative pathway when licensed trimethoprim-sulfonamide products are unavailable. The formulation addition ratio is 100.0 mg sodium sulfacetamide per size 3 hard gelatin capsule, diluted to a total fill weight of 130.0 mg with lactose monohydrate, representing 76.9% w/w active loading. The downstream production process uses a V-blender at 25 rpm for 20 min to disperse the API, followed by encapsulation on a micro-dosing auger machine at 6000 capsules/h; weight uniformity is verified every 10 min with a target rejection limit of ±5.0% from mean fill weight. The terminal product type is a size 3 hard gelatin capsule dispensed in a tight, light-resistant container for single-patient veterinary use.

This pathway is an extemporaneous compounding application rather than an approved systemic indication in FDA, EMA, or VICH-aligned markets. The governing standards are USP <795> for non-sterile compounding, USP <905> for uniformity of dosage units, and USP <1231> for water activity considerations in powder blending. Published data for this specific configuration is limited, and the compounding decision must be justified by culture and susceptibility results, species-specific pharmacokinetic review, and the absence of a licensed alternative. The product is not for food-producing animals, and the label must state this restriction unambiguously. Batch records should document lactose compatibility with sulfacetamide sodium under 25°C/60% RH conditions for 30 days; discoloration or moisture uptake beyond 1.0% water activity indicates capsule shell cross-linking risk and requires rejection.